2020 FDA Medical science Safety 
European Pharmaceutical Review
DECEMBER 28, 2023
We received encouraging feedback from the US Food and Drug Administration (FDA) on the trial design and potential for accelerated approval. These efficacy results, combined with the safety profile that allows patients to complete their treatment regimen, are extremely encouraging. later acquired by Eli Lilly and Company.
European Pharmaceutical Review
FEBRUARY 22, 2023
Of the 175 new drugs approved by the US Food and Drug Administration (FDA) between 2016 and 2019, most were biologics. Results from the first open-label, single-centre study of RT-101,6 which was conducted in Australia, were reported at the start of 2020. Biologics represent an increasingly large part of the pharmaceutical industry.
Expert insights. Personalized for you.
84 
Let's personalize your content